Next generation of rapid-acting antidepressants: Can ketamine help prevent suicide?

Naghmeh Nikkheslat is a Senior Research Associate at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) who is working on a project funded by the NIHR Maudsley BRC to investigate the use of ketamine as a medication for depression. In this blog, she talks about her research into depression and the immune system and what we currently know about ketamine as an anti-inflammatory antidepressant in psychiatric emergencies.

By NIHR Maudsley BRC at 10 Jan 2022
Read more >

New study demonstrates link between brain chemical and visual processing in autism

Researchers from King’s College London and South London and Maudsley NHS Foundation Trust have shown that there are variations in how a brain chemical called GABA regulates the processing of visual stimuli. The study showed that when autistic people are given a drug that activates GABA targets, their visual processing becomes more like that of non-autistic people.

 

By NIHR Maudsley BRC at 6 Jan 2022
Read more >

Psilocybin, in 10mg or 25mg doses, has no detrimental effects in healthy people

New research from King’s College London, in partnership with COMPASS Pathways and supported by NIHR Maudsley BRC, has established that psilocybin can be safely administered at doses of either 10mg or 25mg to up to six participants at the same time.

By NIHR Maudsley BRC at 4 Jan 2022
Read more >

No convincing scientific evidence that hangover cures work, according to new research

A new systematic review has found only very low-quality evidence that substances claiming to treat or prevent alcohol-induced hangover work.

By NIHR Maudsley BRC at 1 Jan 2022
Read more >